Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma - Moderna Investor Relations
- Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Moderna Investor Relations
- Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says CNBC
- Moderna's stock rallies after announcement of positive data from trial of melanoma treatment combined with Merck's Keytruda MarketWatch
- Experimental cancer vaccine, combined with immunotherapy, continues to show benefits against melanoma, trial shows CNN
- Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy Yahoo Finance